Surmodics, Inc. announced results from a sex-specific analysis of its ongoing PROWL registry evaluating real-world use of the ...
Mistry described Scp776 as a “designer drug.” She explained that IGF-1 receptors are abundant throughout the body, and IGF-1 ...
1don MSN
General anesthesia during clot-removal surgery leads to better neurological outcomes at 3 months
Patients who undergo general anesthesia while receiving a specialized surgery to treat strokes have better outcomes than ...
Functional recovery after EVT for AIS varies by race and ethnicity, even though procedural success is similar across groups.
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care ...
Pat has a strong track record as a seasoned and strategic leader of medical technology companies, helping them catalyze new markets and scale internationally,” said Tony Chou, Chief Executive Officer ...
Even patients with stroke with excellent functional recovery can experience significant, adverse nonmotor outcomes 6 months ...
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke ...
The tablets are to reduce the risk of cardiovascular death, myocardial infarction (MI) and stroke in patients with acute ...
Surmodics (Nasdaq:SRDX) announced results from a sex-specific analysis of real-world patients in a study of its Pounce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback